News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rituximab Ups Survival in Chronic Lymphocytic Leukemia (CLL), University of Cologne Study


10/1/2010 6:22:15 AM

MedPageToday -- Adding the monoclonal antibody rituximab (Rituxan) to initial chemotherapy significantly improved progression-free and overall survival in patients with chronic lymphocytic leukemia (CLL), a prospective study found.

Read at MedPageToday
Read at WebMD

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES